Omeros Corporation reported a net loss of $25.4 million, or $0.43 per share, for the second quarter ended June 30, 2025. This is an improvement compared to a net loss of $56.0 million, or $0.97 per share, for the second quarter of 2024.
As of June 30, 2025, the company held $28.7 million in cash and short-term investments, barely above the $25.0 million minimum unrestricted cash required by its Credit Agreement. However, subsequent to quarter-end, Omeros received $20.6 million in net cash proceeds from a registered direct offering on July 28, 2025, and an additional $2.1 million from ATM facility sales through August 14, 2025.
Total operating expenses for Q2 2025 decreased significantly to $32.4 million from $59.2 million in Q2 2024, primarily due to reduced narsoplimab drug substance manufacturing costs and the temporary pausing of certain programs to prioritize the narsoplimab launch. The company also noted a $3.0 million non-cash loss on extinguishment of convertible senior notes related to the May 2025 exchange.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.